NEW YORK, June 25, 2013 /PRNewswire/ --
Dynavax Technologies Corporation
Lifshitz Law Firm announces that a class action suit was filed
in the United States District Court for the Northern District of
California, alleging that Dynavax
Technologies Corporation ("Dynavax" or the "Company") (DVAX) issued
false and misleading statements to investors between April 26, 2012 and June
10, 2013, inclusive (the "Class Period"). On
June 10, 2013, the Company disclosed
that in a meeting with the FDA over its biologic license
application for hepatitis-B vaccine Heplisav, the FDA expressed
that it wanted additional safety data from more patients before
approving the drug. The FDA further expressed that analyzing
Heplisav for smaller groups of patients did not fully address its
concerns and that it would like to see additional safety trials.
Moreover, as previously noted by the FDA, the Company disclosed
that there were ongoing concerns regarding Dynavax's manufacturing
and testing of Heplisav.
For more information, please contact Joshua M. Lifshitz, Esq. by
telephone at (212) 213-6222 Ext. 18 or by sending an e-mail
including your contact information to: info@jlclasslaw.com.
Keynote Systems, Inc.
Lifshitz Law Firm announces an investigation into possible
breaches of fiduciary duty in connection with the proposed sale of
Keynote Systems, Inc. ("Keynote") (KEYN) to an affiliate of
Thoma Bravo, LLC in an all-cash
transaction valued at approximately $395
million or $20.00 per
share.
Lifshitz Law Firm's investigation is focused on whether the
proposed deal provides adequate value to Keynote's
shareholders.
For more information about our investigation, please contact
Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or
by sending an e-mail including your contact information to:
info@jlclasslaw.com.
sTec, Inc.
Lifshitz Law Firm announces an investigation into possible
breaches of fiduciary duty in connection with the proposed sale of
sTec, Inc. ("sTec") to Western Digital® Corporation in a
transaction valued at approximately $340
million in cash, which equates to $6.85 per share.
Lifshitz Law Firm's investigation is focused on whether the
proposed deal provides adequate value to sTec's shareholders.
For more information about our investigation, please contact
Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or
by sending an e-mail including your contact information to:
info@jlclasslaw.com.
Vanguard Health Systems Inc.
Lifshitz Law Firm announces an investigation into possible
breaches of fiduciary duty in connection with the proposed sale of
Vanguard Health Systems Inc. ("Vanguard") (VHS) to Tenet Healthcare
Corporation in a transaction valued at approximately $4.3 billion including the assumption of
$2.5 billion in Vanguard debt or
$21 per share in cash.
Lifshitz Law Firm's investigation is focused on whether the
proposed deal provides adequate value to Vanguard's
shareholders.
For more information about our investigation, please contact
Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or
by sending an e-mail including your contact information to:
info@jlclasslaw.com.
Lifshitz Law Firm is a New
York based law firm with significant experience representing
investors in merger-related shareholder class actions, shareholder
derivative actions, and securities fraud class actions. For
more information about the firm, please visit our website at
www.jlclasslaw.com.
ATTORNEY ADVERTISING. © 2013 Lifshitz Law Firm.
The law firm responsible for this advertisement is Lifshitz
Law Firm, 18 East 41st Street, New York, New York 10017, (212)
213-6222. Prior results do not guarantee or predict a similar
outcome with respect to any future matter.
Contact:
Joshua M. Lifshitz, Esq.
Lifshitz Law Firm
Phone: 212-213-6222
Email: info@jlclasslaw.com
SOURCE Lifshitz Law Firm